Clinical trials: Open-label
Randomized, Open-label
A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV)
A randomized, multicenter, open-label, active-controlled Phase Ib study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of multiple intravaginal doses of GenSci142 in patients with bacterial…
- Conditions
- Randomized, Open-label, Safety, Tolerability
- Trial name
- NCT07663838
- Testing
- GenSci142 capsule, clindamycin phosphate vaginal cream
- Where
- 9 sites in China
- Volunteers
- 42 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Advanced Urothelial Carcinoma, Oral Drug Administration
A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
The goal of this clinical trial is to study the safety and tolerability in all advanced solid tumors, including advanced urothelial carcinoma.
- Conditions
- Advanced Urothelial Carcinoma, Oral Drug Administration, Open Label
- Trial name
- NCT05929235
- Testing
- FX-909, Pembrolizumab (KEYTRUDA ®), KEYTRUDA ®( Pembrolizumab)
- Where
- 12 sites in United States
- Volunteers
- 120 people
- Sponsor
- Flare Therapeutics Inc.
Phase 1b, Open Label
A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy
To learn if the study drug REC-617 can help to control LMS. The safety of REC-617 will also be studied.
- Conditions
- Phase 1b, Open Label, REC-617, RB1-Negative
- Trial name
- NCT07633756
- Testing
- REC617
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Phase II, Open-label, Parallel 2-arm, Multi-center
A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer
Gemcitabine and nab-paclitaxel are one standard of care for metastatic pancreatic adenocarcinoma (mPDAC) but the progression free survival (PFS) of the regimen is only 5.5 months.
- Trial name
- NCT05026905
- Testing
- Gemcitabine 1000 mg, Nab paclitaxel, S1
- Where
- 4 sites in Taiwan
- Volunteers
- 66 people
- Sponsor
- National Health Research Institutes, Taiwan
Pharmakokinetic, Open Label
A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride Sublingual Tablet) In Non-Elderly Versus Elderly Participants
TNX-102 SL has recently been approved by the United States (US) Food and Drug Administration (FDA) under the brand name TONMYA for the treatment of fibromyalgia.
- Conditions
- Pharmakokinetic, Open Label, Phase 1
- Trial name
- NCT07413367
- Testing
- TNX-102 SL Tablet
- Where
- Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Tonix Pharmaceuticals, Inc.
Open-label Placebos
Patients' Attitudes Towards Open-Label Placebo Implementation Into Clinical Practice
The aim of this project is to assess patients' opinions, attitudes, and ideas regarding the administration of OLPs in clinical practice, although they might never have had contact to placebos.
- Trial name
- PATOLP (NCT05166213)
- Testing
- focus group discussions (FGD)
- Where
- Switzerland
- Volunteers
- 6 people
- Sponsor
- University Hospital, Basel, Switzerland
Pharmacokinetics, Open Label
A Study to Investigate the Effect of Administration of Ceftazidime-avibactam (CAZ-AVI) and Ceftaroline Fosamil -Avibactam (CXL) on the Intestinal Flora of Healthy Volunteers
The purpose of this study is to investigate the effect of administration of CAZ-AVI and CXL on the intestinal flora of male and female healthy volunteers after multiple administrations over 7 days.
- Conditions
- Pharmacokinetics, Open Label, CAZ-AVI, CXL
- Trial name
- NCT01789528
- Testing
- CAZ-AVI, CXL
- Where
- Sweden
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Pfizer